Interpretation of 2020 American College of Rheumatology Guideline for the Management of Gout from the Perspective of General Practitioners

doi:10.12114/j.issn.1007-9572.2021.00.133

Abstract

Abstract: The recent updates of guidelines for the management of gout have gradually promoted the standardization of gout diagnosis and treatment. What's more，the newly released 2020 American College of Rheumatology Guideline for the Management of Gout has made some vague concepts to be clear. As general practitioners play a vital role in the management of gout，a common and frequently-occurring disease，we interpreted the 2020 American College of Rheumatology Guideline for the Management of Gout from their perspective，and compared it to the latest Chinese guideline for the management of gout，offering proposal ideas to help general practitioners with the diagnosis and treatment of gout.

Key words: Gout, Hyperuricemia, Guideline, General practitioner

摘要：

近年来，国内外痛风治疗指南不断更新，使痛风诊治逐渐变得规范。随着《2020年美国风湿病学会痛风治疗指南》的公布，一些模糊的概念越来越清晰。痛风作为一种常见病、多发病，全科医生在痛风的治疗中起着至关重要的作用。本文将从全科医生的角度论述《2020年美国风湿病学会痛风治疗指南》，并与我国最新版痛风治疗指南进行对比，为全科医生诊治痛风提供参考建议。

关键词: 痛风, 高尿酸血症, 指南, 全科医生

LIU Min,MENG Juan. Interpretation of 2020 American College of Rheumatology Guideline for the Management of Gout from the Perspective of General Practitioners　[J]. Chinese General Practice, 2021, 24(25): 3148-3153. DOI: 10.12114/j.issn.1007-9572.2021.00.133.
刘敏,孟娟. 基于全科医生视角的《2020年美国风湿病学会痛风治疗指南》解读[J]. 中国全科医学, 2021, 24(25): 3148-3153. DOI: 10.12114/j.issn.1007-9572.2021.00.133.

References

［1］中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南（2019）［J］. 中华内分泌代谢杂志，2020，36（1）：1-12. DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
Chinese Society of Endocrinology. Guideline for the Diagnosis and Management of Hyperuricemia and Gout in China（2019）［J］. Chinese Journal of Endocrinology and Metabolism，2020，36（1）：1-12. DOI：10.3760/cma.j.issn.1000-6699.2020.01.001.
［2］FITZGERALD J D，DALBETH N，MIKULS T，et al. 2020 American College of Rheumatology Guideline for the Management of Gout［J］. Arthritis Care Res（Hoboken），2020，72（6）：744-760. DOI：10.1002/acr.24180.
［3］CAMPION E W，GLYNN R J，DELABRY L O. Asymptomatic hyperuricemia risks and consequences in the normative aging study［J］. Am J Med，1987，82（3）：421-426.
［4］KHANNA D，KHANNA P P，FITZGERALD J D，et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1：systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia［J］. Arthritis Care Res（Hoboken），2012，64（10）：1431-1446.
［5］中华医学会. 痛风及高尿酸血症基层诊疗指南（2019年）［J］. 中华全科医师杂志，2020，19（4）：293-303. DOI：10.3760/cma.j.cn114798-20200328-00382.
［6］邹和建. 强基层，提升痛风诊疗水平［J］. 中华全科医师杂志，2020，19（4）：288-289. DOI：10.3760/cma.j.cn114798-20200330-00389.
［7］WHITE W B，SAAG K G，BECKER M A，et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout［J］. N Engl J Med，2018，378（13）：1200-1210. DOI：10.1056/NEJMoa1710895.
［8］YAMMANAKA H，TAMAKI S，IDE Y，et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy：results from FORTUNE-1，a prospective，multicentre randomised study［J］. Ann Rheum Dis，2018，77（2）：270-276. DOI：10.1136/annrheumdis-2017-211574.
［9］ MICHELLE H，ALISON C，STEWART C，et al. The British Society for Rheumatology Guideline for the Management of Gout［J］. Rheumatology，2017，56（7）：1056-1059.
［10］HILL E M，SKY K，SIT M，et al. Does starting allopurinol prolong acute treated gout? A randomized clinical trial［J］. Clin Rheumatol，2015，21（3）：120-125. DOI：10.1097/RHU.0000000000000235.
［11］TAYLOR T H，MECCHELLA J N，LARSON R J，et al. Initiation of allopurinol at first medical contact for acute attacks of gout：a randomized clinical trial［J］. Am J Med，2012，125（11）：1126-1134. DOI：10.1016/j.amjmed.2012.05.025.
［12］DOHERTY M，JENKINS W，RICHARDSON H，et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout：a randomised controlled trial ［J］. Lancet，2018，392（10156）：1403-1412. DOI：10.1016/S0140-6736(18)32158-5.
［13］CHEN C H，CHEN C B，CHANG C J，et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians：a population-based cohort study and meta-analysis［J］. Clinical Pharmacology and Therapeutics，2019，106（2）：391-401. DOI：10.1002/CPT.1377.
［14］MOHAMED O，CARL S，LI J，et al. Dipstick spot urine pH does not accurately represent 24 hour urine pH measured by an electrode［J］. Int Braz J Urol，2016，42（3）：546-549. DOI：10.1590/S1677-5538.IBJU.2015.0071.
［15］YU K H，CHEN D Y，CHEN J H，et al. Management of Gout and Hyperuricemia：Multidisciplinary Consensus in Taiwan［J］. International Journal of Rheumatic Diseases，2018，21（4）：772-787. DOI：10.1111/1756-185x.13266.
［16］PEREZ-RUIZ F，CALABOZO M，PIJOAN J I，et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout［J］. Arthritis Rheum，2002，47（4）：356-360. DOI：10.1002/art.10511.
［17］史晓飞，徐东，帅宗文，等. 痛风相关知识问答（二）：痛风急性发作期及预防发作治疗篇［J］. 中华内科杂志，2018，57（10）：759-760. DOI：10.3760/cma.j.issn.0578-1426.2018.10.013.
［18］CHOI H K，ATKINSON K，KARLSON E W，et al. Obesity，weight change，hypertension，diuretic use，and risk of gout in men［J］. Arch Intern Med，2005，165（7）：742-748. DOI：10.1001/archinte.165.7.742.
［19］WALDMAN B，ANSQUER J C，SULLIVAN D R，et al. Effect of fenofibrate on uric acid and gout in type 2 diabetes：a post-hoc analysis of the randomised，controlled FIELD study［J］. Lancet Diabetes Endocrinol，2018，6（4）：310-318. DOI：10.1016/S2213-8587(18)30029-9.

[1]	LU Guangqi, ZHUANG Minghui, ZHU Liguo, GAO Jinghua, WEI Xu, LI Luguang, YU Jie. Interpretation of Best Practices for Minimally Invasive Lumbar Spinal Stenosis Treatment 2.0 (MIST) : Consensus Guidance from the American Society of Pain and Neuroscience (ASPN) in 2022 [J]. Chinese General Practice, 2023, 26(32): 3995-4000.
[2]	ZHANG Peng, GAO Ying, YANG Hongxi, WAN Chunxiao. Association between Serum Uric Acid Level and the Risk of Chronic Kidney Disease among the Elderly in Longevity Areas of China [J]. Chinese General Practice, 2023, 26(31): 3884-3889.
[3]	HE Yingmei, JIA Xue, ZHU Guojun, LIU Bing. Effect of Serum Uric Acid Longitudinal Trajectory on New-onset Hypertriglyceridemia: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(29): 3636-3639.
[4]	SU Guobin, LING Xitao, DUAN Ruolan, ZHANG La, XU Yuan, PENG Yu, HOU Haijing, LIU Xusheng, LU Fuhua. Selection of Therapeutic Drugs for COVID-19 Infection in Adults with Chronic Kidney Disease Based on Medical Evidence [J]. Chinese General Practice, 2023, 26(26): 3220-3229.
[5]	Nursing Group of Chinese Society of Geriatrics, Committee on Geriatric Nursing of Chinese Association of Geriatric Research, China Gerontological Nursing Alliance, National Center of Gerontology, Institute of Geriatric Medicine of Chinese Academy of Medical Sciences, HU Huixiu, ZHAO Yajie, SUN Chao. Clinical Practice Guidelines for Exercise Interventions for the Prevention of Disability in Older Adults (2023) [J]. Chinese General Practice, 2023, 26(22): 2695-2710.
[6]	ZHANG Zhuoran, YU Changhe, AN Yi, HE Xin, GUO Yi, DENG Jinyan, LI Yue, HAN Deng, PI Shanshan, HE Junzhi, CHEN Yue, YE Yong'an, DU Hongbo. Quality Assessment and Recommendations of Clinical Guidelines and Consensuses on Non-alcoholic Fatty Liver Disease: a Comparative Study [J]. Chinese General Practice, 2023, 26(20): 2439-2446.
[7]	ZHU Danmeng, HUANG Yuying, LUO Tong'an, HE Changyuan, CHEN Rilan. Effect of Pricking-bloodletting Therapy Combined with Zhuang-medicine-thread Moxibustion on TLRs/MyD88 Signal Pathway in a Rat Model of Acute Gouty Arthritis [J]. Chinese General Practice, 2023, 26(20): 2525-2531.
[8]	LIU Jingtao, SU He, QIN Xiaojin, LAN Yunxia, ZHANG Jinzhi. Guidelines on Cardiac Rehabilitation in Patients with Coronary Heart Disease: a Systematic Review [J]. Chinese General Practice, 2023, 26(19): 2323-2331.
[9]	ZHANG Lulu, CHEN Huan, LUO Huan, CHEN Tingting, CHEN Xinyu, GAO Jing. Fear of Cancer Recurrence Assessment Tools Based on COSMIN: a Systematic Review [J]. Chinese General Practice, 2023, 26(17): 2138-2146.
[10]	China Gerontological Nursing Alliance, Xiang Ya Nursing School Central South University (Xiangya Oceanwide Health Management Research Institute of Central South University), Xiangya Hospital Central South University (National Clinical Research Center for Geriatric Disorders), Beijing Hospital (National Center for Gerontology, National Clinical Research Center for Geriatric Disorders), LI Mengqi, WU Lina, NING Hongting, FENG Hui. Clinical Practice Guideline for Non-pharmacological Interventions for Malnourished Elderly [J]. Chinese General Practice, 2023, 26(17): 2055-2069.
[11]	XIN Jiadong, ZHOU Jiabao, WU Zhiyuan, ZHANG Xuming, GAO Jiandong. Advances in Urate Excretion and Urate Transporters in Hyperuricemia [J]. Chinese General Practice, 2023, 26(15): 1916-1922.
[12]	SONG Hualong, GAO Ying. Association between Serum Uric Acid and the Risk of Type 2 Diabetes Mellitus: a Population-based Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(15): 1831-1839.
[13]	Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022) [J]. Chinese General Practice, 2023, 26(14): 1671-1691.
[14]	WANG Ping, ZHOU Qi, ZHAO Junxian, WU Shouyuan, SUN Yajia, LAN Hui, REN Mengjuan, SU Renfeng, WANG Ling, WANG Qi, LI Sheyu, HUANG Yanli, WANG Xiaohui, MA Yanfang, MA Li, XU Yanli, SUN Yange, SHI Ling, HUANG Yanyan, HOU Tianchun, GE Long, DU Zhaohui, ZHENG Yanling, YIN Zhaoxia, LI Tingting, ZENG Linan, ZHANG Xiaolong, REN Yanping, LIU Enmei, YI Chuntao, CHEN Yaolong. Development of Reporting Items for Practice Guidelines in Primary Care [J]. Chinese General Practice, 2023, 26(13): 1543-1550.
[15]	WANG Ping, WU Shouyuan, SUN Yajia, LAN Hui, REN Mengjuan, ZHAO Junxian, WANG Ling, SU Renfeng, ZHOU Qi, WANG Zijun, WANG Qi, MA Li, HOU Tianchun, CHEN Yaolong. Current Situation Analysis and Quality Evaluation of Chinese Clinical Practice Guidelines in General Practice [J]. Chinese General Practice, 2023, 26(13): 1551-1558.